Cancer Therapies
Targeted Cancer Therapies
Hepatic Portal System
Tumor Immunotherapy
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Apr 15, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
James J Harding1, Ghassan K Abou-Alfa2
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA. hardinj1@mskcc.org.
Advanced hepatocellular carcinoma (HCC) has a poor prognosis, with sorafenib offering modest benefits. New anti-angiogenic drugs have not surpassed sorafenib, highlighting the need for further molecular research and drug development in HCC.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: